UW Madison
Welcome,         Profile    Billing    Logout  
 20 Trials 
28 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gern, James
CREW, NCT03213184: Children's Respiratory and Environmental Workgroup

Completed
N/A
142
US
University of Wisconsin, Madison, National Institutes of Health (NIH), University of Chicago, University of California, San Francisco, Harvard School of Public Health (HSPH), University of Arizona
Asthma, Allergic Asthma, Allergies, Healthy
06/23
06/23
CANOE, NCT04215783: Childhood Allergy and the Neonatal Environment

Active, not recruiting
N/A
499
US
University of Wisconsin, Madison, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Duke University
Asthma in Children, Allergy
08/25
08/25
URECA, NCT00114881: Urban Environmental Factors and Childhood Asthma

Completed
N/A
560
US
National Institute of Allergy and Infectious Diseases (NIAID), Inner-City Asthma Consortium, Rho Federal Systems Division, Inc.
Asthma, Allergy
08/24
08/24
MARI, NCT06059027: Microbes and Respiratory Illnesses

Recruiting
N/A
350
US
University of Wisconsin, Madison, National Institute of Allergy and Infectious Diseases (NIAID)
Virus, Asthma
12/26
12/27
SUNBEAM, NCT04798079: Systems Biology of Early Atopy

Recruiting
N/A
2500
US
National Institute of Allergy and Infectious Diseases (NIAID), Consortium for Food Allergy Research, Rho Federal Systems Division, Inc.
Allergic Diseases, Food Allergy, Atopic Dermatitis
09/28
09/28
Jarjour, Nizar N
NCT04129931: PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Active, not recruiting
2
395
US
MCT, Breathe Better Diet (BBD), Clazakizumab, Anti-interleukin 6 monoclonal antibody, Anti-IL-6 mAb, BMS-945429, ALD518, Broncho-Vaxom, OM-85 BV VEGETAL, Imatinib Mesylate, Gleevec, Zoleta, Glivec, Ziatir, Cavosonstat, N91115, Placebo
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
12/24
12/24
NCT01760915: University of Wisconsin Severe Asthma Research Program III

Completed
N/A
107
US
NC100182 Hyperpolarized 3He, helium
University of Wisconsin, Madison, National Institutes of Health (NIH), Washington University School of Medicine, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
03/20
12/21
NCT01606826: Severe Asthma Research Program

Active, not recruiting
N/A
1100
US
Milton S. Hershey Medical Center, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
06/26
12/26
Guilbert, Theresa W
SWIFT-2, NCT04718103 / 2020-003611-10: A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Jul 2024 - Dec 2024 : H2'24 - Acceptance of regulatory submission in US (based on SWIFT-1 trial) for asthma
Completed
3
397
Europe, Canada, Japan, US, RoW
GSK3511294, Depemokimab, Placebo
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
04/24
04/24
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Recruiting
3
292
US, RoW
FF/UMEC/VI, ELLIPTA, FF/VI
GlaxoSmithKline
Asthma
01/27
01/27
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Active, not recruiting
3
641
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
05/25
05/25
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1719
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
09/25
09/25
PARK, NCT02570984: Preventing Asthma in High Risk Kids

Active, not recruiting
2
200
US
Omalizumab, Xolair, Placebo, placebo arm
Boston Children's Hospital, National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
01/28
03/28
Jackson, Daniel L
PANDA, NCT05347771: Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents

Recruiting
2
240
US
Dupilumab, Dupixent, IL4Ra mAb, Placebo, Placebo for Dupilumab
National Institute of Allergy and Infectious Diseases (NIAID), Childhood Asthma in Urban Settings (CAUSE), Regeneron Pharmaceuticals, Rho Federal Systems Division, Inc.
Asthma
08/25
12/25
PARK, NCT02570984: Preventing Asthma in High Risk Kids

Active, not recruiting
2
200
US
Omalizumab, Xolair, Placebo, placebo arm
Boston Children's Hospital, National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
01/28
03/28
adored, NCT05003804: Allergic Disease Onset Prevention Study

Active, not recruiting
1/2
264
US, RoW
STMC-103H, Placebo
Siolta Therapeutics, Inc.
Atopic Dermatitis, Type 1 Hypersensitivity
11/24
10/25
CREW, NCT03213184: Children's Respiratory and Environmental Workgroup

Completed
N/A
142
US
University of Wisconsin, Madison, National Institutes of Health (NIH), University of Chicago, University of California, San Francisco, Harvard School of Public Health (HSPH), University of Arizona
Asthma, Allergic Asthma, Allergies, Healthy
06/23
06/23
RACR3, NCT05272241: Registry of Asthma Characterization and Recruitment 3

Recruiting
N/A
1500
US
National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
05/28
05/28
Fain, Sean
NCT04855305: Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

Recruiting
2
147
US
Hyperpolarized 129Xe
Bastiaan Driehuys, National Heart, Lung, and Blood Institute (NHLBI), Children's Hospital Medical Center, Cincinnati, University of Cincinnati, University of Iowa
Interstitial Lung Diseases
12/25
12/25
(XeRTLC), NCT06925295: Using Xe MRI to Guide Radiation Therapy for Lung Cancer

Not yet recruiting
2
15
NA
Xenon MRI, Pulmonary Function Testing, Quality of Life Questionnaire, Medical Research Council Dyspnea score, St. George's Respiratory Questionnaire, Blood Biomarkers
Sean Fain
Imaging Techniques
01/27
01/27
NCT06406777: Chronic Lung Allograft Dysfunction MRI Study

Recruiting
1/2
100
US
Spirometry, Contrast Lung Computed Tomography (CT) Scan, Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan, 129Xe MRI scans
Sean Fain
Chronic Lung Allograft Dysfunction Lung MRI (CLAD)
09/28
09/28
NCT06191640: Sinus Disease in Young Children With Cystic Fibrosis

Recruiting
N/A
80
US
Ivacaftor or elexacaftor/tezacaftor/ivacaftor, Kalydeco or Trikafta; Vertex (VX)-770 or VX-445/VX-661/VX-770
University of California, Los Angeles, University of Kansas Medical Center, Children's Hospital Medical Center, Cincinnati, University of Iowa, University of Virginia, Children's Hospital Colorado, University of Vermont
Cystic Fibrosis in Children, Cystic Fibrosis, Chronic Rhinosinusitis (Diagnosis), Olfactory Disorder, Olfactory Impairment
04/26
04/26
Denlinger, Loren
GRAIL^3, NCT04706507: Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis

Active, not recruiting
3
500
US
IV Ganciclovir, Cytovene
Fred Hutchinson Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Acute Respiratory Failure
10/24
08/27
NCT04129931: PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Active, not recruiting
2
395
US
MCT, Breathe Better Diet (BBD), Clazakizumab, Anti-interleukin 6 monoclonal antibody, Anti-IL-6 mAb, BMS-945429, ALD518, Broncho-Vaxom, OM-85 BV VEGETAL, Imatinib Mesylate, Gleevec, Zoleta, Glivec, Ziatir, Cavosonstat, N91115, Placebo
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
12/24
12/24
NCT04543461: American Lung Association (ALA) Lung Health Cohort

Recruiting
N/A
4000
US
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University
Lung Diseases
09/26
09/26
NCT01606826: Severe Asthma Research Program

Active, not recruiting
N/A
1100
US
Milton S. Hershey Medical Center, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
06/26
12/26
Goss, Kara N
NCT04968210: Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)

Completed
N/A
3
US
Hyperpolarized 13C-pyruvate
University of Texas Southwestern Medical Center
Pulmonary Arterial Hypertension
12/24
12/24
PHAR, NCT04071327: Pulmonary Hypertension Association Registry

Recruiting
N/A
3000
US
Pulmonary Hypertension Association, Inc., University of Washington, the Collaborative Health Studies Coordinating Center
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
10/25
10/25
Nestler, Jeni A
No trials found
Tisler, Christopher
No trials found
Francour, Jillian
No trials found
Wollet, Lori
No trials found
Drezner, Marc K
No trials found
Palas, Tina M
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gern, James
CREW, NCT03213184: Children's Respiratory and Environmental Workgroup

Completed
N/A
142
US
University of Wisconsin, Madison, National Institutes of Health (NIH), University of Chicago, University of California, San Francisco, Harvard School of Public Health (HSPH), University of Arizona
Asthma, Allergic Asthma, Allergies, Healthy
06/23
06/23
CANOE, NCT04215783: Childhood Allergy and the Neonatal Environment

Active, not recruiting
N/A
499
US
University of Wisconsin, Madison, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Duke University
Asthma in Children, Allergy
08/25
08/25
URECA, NCT00114881: Urban Environmental Factors and Childhood Asthma

Completed
N/A
560
US
National Institute of Allergy and Infectious Diseases (NIAID), Inner-City Asthma Consortium, Rho Federal Systems Division, Inc.
Asthma, Allergy
08/24
08/24
MARI, NCT06059027: Microbes and Respiratory Illnesses

Recruiting
N/A
350
US
University of Wisconsin, Madison, National Institute of Allergy and Infectious Diseases (NIAID)
Virus, Asthma
12/26
12/27
SUNBEAM, NCT04798079: Systems Biology of Early Atopy

Recruiting
N/A
2500
US
National Institute of Allergy and Infectious Diseases (NIAID), Consortium for Food Allergy Research, Rho Federal Systems Division, Inc.
Allergic Diseases, Food Allergy, Atopic Dermatitis
09/28
09/28
Jarjour, Nizar N
NCT04129931: PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Active, not recruiting
2
395
US
MCT, Breathe Better Diet (BBD), Clazakizumab, Anti-interleukin 6 monoclonal antibody, Anti-IL-6 mAb, BMS-945429, ALD518, Broncho-Vaxom, OM-85 BV VEGETAL, Imatinib Mesylate, Gleevec, Zoleta, Glivec, Ziatir, Cavosonstat, N91115, Placebo
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
12/24
12/24
NCT01760915: University of Wisconsin Severe Asthma Research Program III

Completed
N/A
107
US
NC100182 Hyperpolarized 3He, helium
University of Wisconsin, Madison, National Institutes of Health (NIH), Washington University School of Medicine, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
03/20
12/21
NCT01606826: Severe Asthma Research Program

Active, not recruiting
N/A
1100
US
Milton S. Hershey Medical Center, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
06/26
12/26
Guilbert, Theresa W
SWIFT-2, NCT04718103 / 2020-003611-10: A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Jul 2024 - Dec 2024 : H2'24 - Acceptance of regulatory submission in US (based on SWIFT-1 trial) for asthma
Completed
3
397
Europe, Canada, Japan, US, RoW
GSK3511294, Depemokimab, Placebo
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
04/24
04/24
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Recruiting
3
292
US, RoW
FF/UMEC/VI, ELLIPTA, FF/VI
GlaxoSmithKline
Asthma
01/27
01/27
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Active, not recruiting
3
641
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
05/25
05/25
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1719
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
09/25
09/25
PARK, NCT02570984: Preventing Asthma in High Risk Kids

Active, not recruiting
2
200
US
Omalizumab, Xolair, Placebo, placebo arm
Boston Children's Hospital, National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
01/28
03/28
Jackson, Daniel L
PANDA, NCT05347771: Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents

Recruiting
2
240
US
Dupilumab, Dupixent, IL4Ra mAb, Placebo, Placebo for Dupilumab
National Institute of Allergy and Infectious Diseases (NIAID), Childhood Asthma in Urban Settings (CAUSE), Regeneron Pharmaceuticals, Rho Federal Systems Division, Inc.
Asthma
08/25
12/25
PARK, NCT02570984: Preventing Asthma in High Risk Kids

Active, not recruiting
2
200
US
Omalizumab, Xolair, Placebo, placebo arm
Boston Children's Hospital, National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
01/28
03/28
adored, NCT05003804: Allergic Disease Onset Prevention Study

Active, not recruiting
1/2
264
US, RoW
STMC-103H, Placebo
Siolta Therapeutics, Inc.
Atopic Dermatitis, Type 1 Hypersensitivity
11/24
10/25
CREW, NCT03213184: Children's Respiratory and Environmental Workgroup

Completed
N/A
142
US
University of Wisconsin, Madison, National Institutes of Health (NIH), University of Chicago, University of California, San Francisco, Harvard School of Public Health (HSPH), University of Arizona
Asthma, Allergic Asthma, Allergies, Healthy
06/23
06/23
RACR3, NCT05272241: Registry of Asthma Characterization and Recruitment 3

Recruiting
N/A
1500
US
National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
05/28
05/28
Fain, Sean
NCT04855305: Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

Recruiting
2
147
US
Hyperpolarized 129Xe
Bastiaan Driehuys, National Heart, Lung, and Blood Institute (NHLBI), Children's Hospital Medical Center, Cincinnati, University of Cincinnati, University of Iowa
Interstitial Lung Diseases
12/25
12/25
(XeRTLC), NCT06925295: Using Xe MRI to Guide Radiation Therapy for Lung Cancer

Not yet recruiting
2
15
NA
Xenon MRI, Pulmonary Function Testing, Quality of Life Questionnaire, Medical Research Council Dyspnea score, St. George's Respiratory Questionnaire, Blood Biomarkers
Sean Fain
Imaging Techniques
01/27
01/27
NCT06406777: Chronic Lung Allograft Dysfunction MRI Study

Recruiting
1/2
100
US
Spirometry, Contrast Lung Computed Tomography (CT) Scan, Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan, 129Xe MRI scans
Sean Fain
Chronic Lung Allograft Dysfunction Lung MRI (CLAD)
09/28
09/28
NCT06191640: Sinus Disease in Young Children With Cystic Fibrosis

Recruiting
N/A
80
US
Ivacaftor or elexacaftor/tezacaftor/ivacaftor, Kalydeco or Trikafta; Vertex (VX)-770 or VX-445/VX-661/VX-770
University of California, Los Angeles, University of Kansas Medical Center, Children's Hospital Medical Center, Cincinnati, University of Iowa, University of Virginia, Children's Hospital Colorado, University of Vermont
Cystic Fibrosis in Children, Cystic Fibrosis, Chronic Rhinosinusitis (Diagnosis), Olfactory Disorder, Olfactory Impairment
04/26
04/26
Denlinger, Loren
GRAIL^3, NCT04706507: Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis

Active, not recruiting
3
500
US
IV Ganciclovir, Cytovene
Fred Hutchinson Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Acute Respiratory Failure
10/24
08/27
NCT04129931: PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Active, not recruiting
2
395
US
MCT, Breathe Better Diet (BBD), Clazakizumab, Anti-interleukin 6 monoclonal antibody, Anti-IL-6 mAb, BMS-945429, ALD518, Broncho-Vaxom, OM-85 BV VEGETAL, Imatinib Mesylate, Gleevec, Zoleta, Glivec, Ziatir, Cavosonstat, N91115, Placebo
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
12/24
12/24
NCT04543461: American Lung Association (ALA) Lung Health Cohort

Recruiting
N/A
4000
US
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University
Lung Diseases
09/26
09/26
NCT01606826: Severe Asthma Research Program

Active, not recruiting
N/A
1100
US
Milton S. Hershey Medical Center, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
06/26
12/26
Goss, Kara N
NCT04968210: Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)

Completed
N/A
3
US
Hyperpolarized 13C-pyruvate
University of Texas Southwestern Medical Center
Pulmonary Arterial Hypertension
12/24
12/24
PHAR, NCT04071327: Pulmonary Hypertension Association Registry

Recruiting
N/A
3000
US
Pulmonary Hypertension Association, Inc., University of Washington, the Collaborative Health Studies Coordinating Center
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
10/25
10/25
Nestler, Jeni A
No trials found
Tisler, Christopher
No trials found
Francour, Jillian
No trials found
Wollet, Lori
No trials found
Drezner, Marc K
No trials found
Palas, Tina M
No trials found

Download Options